Drug Shortage Report for VISKAZIDE
Report ID | 151235 |
Drug Identification Number | 00568635 |
Brand name | VISKAZIDE |
Common or Proper name | HYDROCHLOROTHIAZIDE PINDOLOL |
Company Name | XEDITON PHARMACEUTICALS INC |
Market Status | MARKETED |
Active Ingredient(s) | HYDROCHLOROTHIAZIDE PINDOLOL |
Strength(s) | 50MG 10MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 3x35 Tablets |
ATC code | C07CA |
ATC description | BETA BLOCKING AGENTS AND OTHER DIURETICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-12-20 |
Actual start date | |
Estimated end date | 2022-01-31 |
Actual end date | 2022-04-13 |
Shortage status | Resolved |
Updated date | 2022-04-27 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2020 WINSTON PARK DRIVE OAKVILLE, ONTARIO CANADA L6H 6X7 |
Company contact information | george.gafrey@xediton.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2021-12-15 | English | Compare |
v2 | 2021-12-15 | French | Compare |
v3 | 2021-12-21 | English | Compare |
v4 | 2022-04-27 | English | Compare |
v5 | 2022-04-27 | French | Compare |
Showing 1 to 5 of 5